Drug Development
PRO 542 shows promise as HIV salvage therapy
Published in AIDS Weekly, March 22nd, 2004
"Viral entry inhibitors represent an emerging mode of therapy for human immunodeficiency virus type I (HIV-1) infection," scientists in New York noted. "PRO 542 (CD4-immunoglobulin G2) is a tetravalent CD4-immunoglobulin fusion protein that broadly neutralizes primary HIV-1 isolates."
"PRO 542 binds to the viral surface glycoprotein gp120 and blocks attachment and entry of virus into CD4+ cells," J.N. Jacobson and colleagues at Mount Sinai Medical Center explained. "Previously, PRO 542 demonstrated antiviral activity without significant toxicity when tested at single doses ranging to...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2004-03-22)
More Articles from AIDS Weekly
- Drug Development
PBD hybrids disrupt HIV RNA activity - Drug Development
Benzothiepine and benzazepine derivatives show promise as oral CCR5 blockers - Drug Development
Small molecules with novel antiretroviral mechanisms developed - HIV/AIDS Dementia
Elevated ceramide production may underlie HIV neurotoxicity - HIV/AIDS Dementia
JNK/p38 inhibitors may protect against HIV-induced CNS disease - Biotechnology
DNA chip offers simultaneous detection of HIV, HBV and HCV in blood - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
